4846 Federal Register / Vol. 66, No. 12 / Thursday, January 18, 2001 / Notices

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse;

Notice of Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The contract proposals and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the contract

proposals, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute on

Drug Abuse Special Emphasis Panel, ‘‘Novel

Drug Delivery System for the Mouse’’.

Date: January 11, 2001.

Time: 11 a.m. to 1 p.m.

Agenda: To review and evaluate contract

proposals.

Place: Neuroscience Center, National

Institutes of Health, 6001 Executive Blvd.,

Bethesda, MD 20892, (Telephone Conference

Call).

Contact Person: Richard C. Harrison, Chief,

Contract Review Branch, Office of Extramural

Affairs, National Institute on Drug Abuse,

National Institutes of Health, 6001 Executive

Boulevard, Room 3158, MSC 9547, Bethesda,

MD 20892–9547, 301–435–1437.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: National Institute on

Drug Abuse, Special Emphasis Panel,

‘‘Chemical Libraries for Drug Development’’.

Date: January 18, 2001.

Time: 1 p.m. to 3 p.m.

Agenda: To review and evaluate contract

proposals.

Place: Neuroscience Center, National

Institutes of Health, 6001 Executive Blvd.,

Bethesda, MD 20892, (Telephone Conference

Call).

Contact Person: Eric Zatman, Contract

Review Specialist, Office of Extramural

Affairs, National Institute on Drug Abuse,

National Institutes of Health, DHHS, 6001

Executive Boulevard, Room 3158, MSC 9547,

Bethesda, MD 20892–9547, 301–435–1438.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: National Institute on

Drug Abuse Special Emphasis Panel,

‘‘Development of Science Education

Materials or Programs’’.

Date: January 31, 2001.

Time: 9 a.m. to 5 p.m.

Agenda: To review and evaluate contract

proposals.

Place: Gaithersburg Marriott

Washingtonian Center, 9751 Washingtonian

Boulevard, Gaithersburg, MD 20878.

Contact Person: Lyle Furr, Contract Review

Specialist, Office of Extramural Affairs,

National Institute on Drug Abuse, National

Institutes of Health, DHHS, 6001 Executive

Boulevard, Room 3158, MSC 9547, Bethesda,

MD 20892–9547, 301–435–1439.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.277, Drug Abuse Scientist

Development Award for Clinicians, Scientist

Development Awards, and Research Scientist

Awards; 93.278, Drug Abuse National

Research Service Awards for Research

Training; 93.279, Drug Abuse Research

Programs, National Institutes of Health, HHS)

Dated: January 10, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–1461 Filed 1–17–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and

Digestive and Kidney Diseases; Notice

of Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Diabetes and Digestive and Kidney Diseases

Special Emphasis Panel, ZDK1 GRB–5(C2)B.

Date: January 24, 2001.

Time: 3 p.m. to 5 p.m.

Agenda: To review and evaluate contract

proposals.

Place: 2 Democracy Plaza, Room 654,

Bethesda, MD 20892, (Telephone Conference

Call).

Contact Person: Francisco O. Calvo, PhD.,

Acting Chief, Review Branch, DEA, NIDDK,

Room 655, 6707 Democracy Boulevard,

National Institutes of Health, Bethesda, MD

20892–6600, (301) 594–8897.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: National Institute of

Diabetes and Digestive and Kidney Diseases

Special Emphasis Panel, ZDK1 GRB–2(C2)B.

Date: February 15, 2001.

Time: 4 p.m. to 5 p.m.

Agenda: To review and evaluate contract

proposals.

Place: 2 Democracy Plaza, 6707 Democracy

Boulevard, Room 643, Bethesda, MD 20892,

(Telephone Conference Call).

Contact Person: Shan S. Wong, PhD.,

Scientific Review Administrator, Review

Branch, DEA, NIDDK, Room 643, 6707

Democracy Boulevard, National Institutes of

Health, Bethesda, MD 20892, (301) 594–7797.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name of Committee: National Institute of

Diabetes and Digestive and Kidney Diseases

Initial Review Group Diabetes,

Endocrinology and Metabolic Diseases B

Subcommittee.

Date: March 8–9, 2001.

Time: 8 a.m. to 5 p.m.

Agenda: To review and evaluate grant

applications.

Place: Four Points by Sheraton Bethesda,

8400 Wisconsin Avenue, Bethesda, MD

20814.

Contact Person: Michele L. Barnard, PhD.,

Scientific Review Administrator, Review

Branch, DEA, NIDDK, National Institutes of

Health, Room 657, 6707 Democracy

Boulevard, Bethesda, MD 20892, (301) 594–

8898.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.847, Diabetes,

Endocrinology and Metabolic Research;

93.848, Digestive Diseases and Nutrition

Research; 93.849, Kidney Diseases, Urology

and Hematology Research, National Institutes

of Health, HHS)

Dated: January 10, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–1462 Filed 1–17–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Library of Medicine; Notice of

Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of a meeting of the

Board of Regents of the National Library

of Medicine.

The meeting will be open to the

public as indicated below, with

attendance limited to space available.

Individuals who plan to attend and

need special assistance, such as sign

Federal Register / Vol. 66, No. 12 / Thursday, January 18, 2001 / Notices 4847

language interpretation or other

reasonable accommodations, should

notify the Contact Person listed below

in advance of the meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications

and/or contract proposals and the

discussions could disclose confidential

trade secrets or commercial property

such as patentable material, and

personal information concerning

individuals associated with the grant

applications and/or contract proposals,

the disclosure of which would

constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: Board of Regents of

the National Library of Medicine.

Date: February 27–28, 2001.

Open: February 27, 2001, 9:00 am to 4:40

pm.

Agenda: Administrative Reports and

Program Discussion.

Place: National Library of Medicine, Board

Room, Bldg 38, 2E–09, 8600 Rockville Pike,

Bethesda, MD 20894.

Closed: February 27, 2001, 4:40 pm to 5:00

pm.

Agenda: To review and evaluate grant

applications.

Place: National Library of Medicine, Board

Room, Bldg 38, 2E–09, 8600 Rockville Pike,

Bethesda, MD 20894.

Open: February 28, 2001, 9:15 am to 11:30

am.

Agenda: Administrative Reports and

Program Discussion.

Place: National Library of Medicine, Board

Room, Bldg 38, 2E–09, 8600 Rockville Pike,

Bethesda, MD 20894.

Contact Person: Donald A.B. Lindberg, MD,

Director, National Library of Medicine,

National Institutes of Health, PHS, DHHS,

Bldg 38, Room 2E17B, Bethesda, MD 20894.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.879, Medical Library

Assistance, National Institutes of Health,

HHS)

Dated: January 9, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 01–1458 Filed 1–17–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Method for Preparing 17αAcetoxy-11β-(4-,N-Dimethylaminophyl)-

19-Norpregna-4, 9-Diene-3,20-Dione,

Intermediates Useful in the Method,

and Methods for the Preparation of

Such Intermediates

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: U.S. Patent

Application Serial No. 08/413,755, filed

March 30, 1995, issuing as U.S. Patent

5,929,262 entitled, ‘‘Method for

Preparing 17α-Acetoxy-11β-(4-N,NDimethylaminophyl)-19-Norpregna-4, 9-

Diene-3,20-Dione, Intermediates Useful

in the Method, and Methods for the

Preparation of such Intermediates’’ to

HRA Pharma, a corporation of France,

having a place of business in Paris,

France. The patent rights in this

invention have been assigned to the

United States of America, as represented

by the Department of Health and Human

Services.

DATES: Only written comments and/or

application for a license which are

received by the NIH Office of

Technology Transfer on or before April

18, 2001 will be considered.

ADDRESSES: Requests for a copy of the

patent applications, inquiries,

comments and other materials relating

to the contemplated license should be

directed to: Dennis H. Penn, Pharm.D.,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville, MD

20852–3804; Telephone: (301) 496–

7056, ext. 211; Facsimile: (301) 402–

0220.

SUPPLEMENTARY INFORMATION: In an

effort to develop an efficacious

treatment for human reproductive

disorders this invention describes

methods for the synthesis of 17αAcetoxy-11β-(4-N,NDimethylaminophyl)-19-Norpregna-4,9-

Diene-3,20-Dione Intermediates Useful

in the Method, and Methods for the

Preparation of such Intermediates This

compound may have utility in treating

human reproductive disorders and

hormone sensitive tumors.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless,

within 90 days from the date of this

published Notice, NIH received written

evidence and argument that establishes

that the grant of the license would not

be consistent with the requirements of

35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to the

use of the invention for the synthesis

17α-Acetoxy-11β-(4-N,NDimethylaminophyl)-19-Norpregna-4, 9-

Diene-3,20-Dione and intermediates

useful in the method of synthesis and

preparation of such intermediates.

Properly filed competing applications

for a license filed in response to this

notice will be treated as objections to

the contemplated license. Comments

and objections submitted in response to

this notice will not be made available

for public inspection, and, to the extent

permitted by law, will not be released

under the Freedom of Information Act,

5 U.S.C. 552.

Dated: January 8, 2001.

Jack Spiegel,

Director, Division of Technology Development

and Transfer, Office of Technology Transfer.

[FR Doc. 01–1465 Filed 1–17–01; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive

License: Orally Active Derivatives of

1,3,5(10)-Estratriene

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(i), that the National

Institutes of Health (NIH), Department

of Health and Human Services, is

contemplating the grant of an exclusive

license worldwide to practice the

invention embodied in: U.S. Patent

Application Series No. 08/122,853, filed

September 17, 1993, issuing as U.S.

Patent 5,554,603 on September 10, 1996

entitled, ‘‘Orally Active Derivatives of

1,3,5(10)-Estratriene’’ to the R.W.

Johnson Pharmaceutical Research

Institute, a corporation of Delaware,

having a place of business in Raritan,

New Jersey. The patent rights in this

invention have been assigned to the